Search results
Results from the WOW.Com Content Network
Together, the disorders caused by PTEN mutations are called PTEN hamartoma tumor syndromes, or PHTS. Mutations responsible for these syndromes cause the resulting protein to be non-functional or absent. The defective protein allows the cell to divide in an uncontrolled way and prevents damaged cells from dying, which can lead to the growth of ...
Inhibiting different p110 isoforms can have different effects, [15] e.g. PTEN-negative tumors may be more sensitive to PIK3CB inhibitors. [15] PI3K inhibitors are also under investigation as treatments for inflammatory respiratory disease, [13] [16] and are used to investigate the role of the PI3K pathway in aging. [17]
B-cell Hodgkin's lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia Camrelizumab [22] mab: humanized: PD-1: hepatocellular carcinoma: Canakinumab [43] Ilaris: mab: human: IL-1: Y: cryopyrin-associated periodic syndrome, Yao's Syndrome, Adult Onset Still's Disease: Cantuzumab mertansine [42] mab: humanized ...
Antileukemic drugs, anticancer drugs that are used to treat one or more types of leukemia, include: [1] 6-Mercaptopurine; 6-Thioguanine; Arsenic trioxide; Asparaginase;
Specifically, it has an important role in tumorigenesis in PTEN-negative cancers. [15] It's reported that interfering with the gene for PI3Kb might be a therapeutic approach for high-risk bladder cancers with mutant PTEN and E-cadherin loss. Specific isoform inhibitors to PI3Kb is a potential treatment for PTEN-deficient cancers. [16]
Beremagene geperpavec (Vyjuvek): treatment of wounds. [2] Betibeglogene autotemcel (Zynteglo): treatment for beta thalassemia [3] Brexucabtagene autoleucel (Tecartus): treatment for mantle cell lymphoma and acute lymphoblastic leukemia [4] [5] Cambiogenplasmid (Neovasculgen): treatment for vascular endothelial growth factor peripheral artery ...
Some of the substances require conversion into active substances in vivo (e.g., cyclophosphamide).. Cyclophosphamide is one of the most potent immunosuppressive substances. In small dosages, it is very efficient in the therapy of systemic lupus erythematosus, autoimmune hemolytic anemia, granulomatosis with polyangiitis, and other autoimmune diseases.
The drug (originally known as MT103) was developed by a German-American company Micromet, Inc. in cooperation with Lonza; In 2012, Micromet was purchased by Amgen, which furthered the drug's clinical trials. In July 2014, the FDA granted breakthrough therapy status to blinatumomab for the treatment of acute lymphoblastic leukemia (ALL). [12]